PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

Pre-exposure prophylaxis, or PrEP, is part of the daily routine for a growing number of Canadians at risk of exposure to HIV through sex or injection drugs. While most people take it in pill ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...

US funding cuts will lead to an additional 2,000 new HIV infections each day and over six million further deaths over the ...

She’d acquired HIV as a college student in the 1980s, she told the audience at an infectious disease conference in San ...

Leronlimab, a weekly injection for people who’ve become resistant to HIV treatment, has seen success in clinical trials. It’s also received a “Fast Track” designation from the FDA ...

Julia Marcus, a Harvard Medical School infectious disease epidemiologist, recently lost three federal grants for research ...

Engineers devised a way to deliver drugs such as contraceptives by injecting them as suspended crystals. Once under the skin, the crystals assemble into a drug depot that can last for months or years, ...

One of the most notable trends in the HIV drugs market is the development of long-acting injectable antiretrovirals, which provide a convenient alternative to daily oral medications. These ...

Novel drug delivery approach that utilizes long-acting injectable microcrystals may enable new options for long-term delivery of contraceptives.

The long-acting injectable drug for PrEP, cabotegravir, sold under the brand name Apretude, was approved by Health Canada in 2024 to reduce the risk of sexually acquired HIV. The antiretroviral ...